Literature DB >> 8095649

Hepatic toxicity of liposomal encapsulated doxorubicin.

R J Coker, N D James, J S Stewart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8095649     DOI： 10.1016/0140-6736(93)90525-l

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.

Authors:  A J Coukell; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 2.  Liposomal formulations of cytotoxic drugs.

Authors:  R Janknegt
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

Review 3.  Safety aspects of pegylated liposomal doxorubicin in patients with cancer.

Authors:  D S Alberts; D J Garcia
Journal:  Drugs       Date:  1997       Impact factor: 9.546

4.  Phytic acid-modified CeO2 as Ca2+ inhibitor for a security reversal of tumor drug resistance.

Authors:  Zhimin Tian; Junlong Zhao; Shoujie Zhao; Huicheng Li; Zhixiong Guo; Zechen Liang; Jiayuan Li; Yongquan Qu; Dongfeng Chen; Lei Liu
Journal:  Nano Res       Date:  2022-01-29       Impact factor: 10.269
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.